Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:ESRX
Previous Symbol
CUSIP30219G10
Phone314-996-0900
Debt
Debt-to-Equity Ratio0.63
Current Ratio0.77
Quick Ratio0.65
Price-To-Earnings
Trailing P/E Ratio13.42
Forward P/E Ratio10.49
P/E Growth1.23
Sales & Book Value
Annual Sales$100.06 billion
Price / Sales0.54
Cash Flow$10.2352 per share
Price / Cash9.31
Book Value$32.00 per share
Price / Book2.98
Profitability
EPS (Most Recent Fiscal Year)$7.10
Net Income$4.52 billion
Net Margins4.83%
Return on Equity25.43%
Return on Assets8.94%
Miscellaneous
Employees26,600
Outstanding Shares563,860,000
Market Cap$55.06 billion
OptionableOptionable
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts announced that its board has approved a share buyback plan on Wednesday, December 20th 2017, which permits the company to buyback 45,000,000 shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding Co (NASDAQ:ESRX) released its earnings results on Wednesday, October, 31st. The company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.42 by $0.01. The company earned $25.56 billion during the quarter, compared to the consensus estimate of $25.11 billion. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. Express Scripts's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.51 EPS. View Express Scripts' Earnings History.
When is Express Scripts' next earnings date?
What price target have analysts set for ESRX?
18 Wall Street analysts have issued 12 month target prices for Express Scripts' stock. Their forecasts range from $75.00 to $101.00. On average, they anticipate Express Scripts' stock price to reach $89.4286 in the next year. This suggests that the stock has a possible downside of 6.2%. View Analyst Price Targets for Express Scripts.
What is the consensus analysts' recommendation for Express Scripts?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 1 sell rating, 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.
What are Wall Street analysts saying about Express Scripts stock?
Here are some recent quotes from research analysts about Express Scripts stock:
- 1. According to Zacks Investment Research, "Express Scripts ended the third quarter on a solid note, beating the Zacks Consensus Estimate for both the counts. The company has been gaining from strong performance by the core PBM unit. Further, its recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. Developments in the company’s Inside Rx program buoy optimism. The company is also getting acquired by Cigna by December 2018. Express Scripts’ stock has outperformed the industry in the past year. However, Express Scripts currently faces persistent drug pricing issue. Express Scripts announced that its biggest customer and leading health insurer Anthem is not likely to extend the PBM agreement with the company anymore. Furthermore, the company has currently suspended share repurchase program because of the merger agreement with Cigna. Express Scripts has not provided any guidance for 2018." (11/20/2018)
- 2. Maxim Group analysts commented, "The company reported slightly better-than-expected 3Q18 results, including higher revenue and relatively inline EPS. ESRX expects its retention rate for the 2018 selling season to exceed 98%, compared to the prior range of 97.5%-98.5%. Due to the pending acquisition, the company is not holding a conference call." (11/1/2018)
Has Express Scripts been receiving favorable news coverage?
Media stories about ESRX stock have trended positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Express Scripts earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Express Scripts' key competitors?
Who are Express Scripts' key executives?
Express Scripts' management team includes the folowing people:
- Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
- Mr. James M. Havel, Exec. VP & CFO (Age 63)
- Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
- Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
- Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dodge & Cox (7.08%), BlackRock Inc. (6.31%), Capital World Investors (2.80%), Capital International Investors (2.10%), Capital Research Global Investors (2.05%) and Macquarie Group Ltd. (1.48%). Company insiders that own Express Scripts stock include Christine Houston, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which major investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Nordea Investment Management AB, American Century Companies Inc., Capital Research Global Investors, Dodge & Cox, Schroder Investment Management Group, Prudential Financial Inc. and Massachusetts Financial Services Co. MA. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin and Mahon Thomas P Mac. View Insider Buying and Selling for Express Scripts.
Which major investors are buying Express Scripts stock?
ESRX stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, FMR LLC, Abrams Capital Management L.P., Canada Pension Plan Investment Board, Janus Henderson Group PLC, York Capital Management Global Advisors LLC, GABELLI & Co INVESTMENT ADVISERS INC. and Morgan Stanley. View Insider Buying and Selling for Express Scripts.
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $95.29.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $55.06 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.
What is Express Scripts' official website?
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
